Biovest International Inc., which exited from bankruptcy protection in July, still faces an uncertain future as it anticipates incurring future losses.

The Tampa-based company develops cancer vaccines, which aim to treat and diminish the aggressiveness of B-cell non-Hodgkin’s lymphoma. The company has a product candidate called Biovax ID that has been evaluated in clinical trials and it pursing marketing approvals. The company also develops and sells Autovax ID, a medical device that develops personalized medicines and other products.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.